Requirements for a Breakthrough Therapy Designation
October 4th 2013Richard Pazdur, MD, director of the Office of Hematology and Oncology Products in FDA’s Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.
Watch
Extending Progression-Free Survival in Ovarian Cancer With Pazopanib
September 25th 2013Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Watch
Potential Therapeutic Targets and Molecular Drivers of Inflammatory Breast Cancer
September 24th 2013Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses the background and results of a study looking at crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).
Watch